Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2014 Nov 10;26(5):605-22. doi: 10.1016/j.ccell.2014.10.006. Epub 2014 Nov 10.

Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

Author information

1
Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, 100 Blossom Street, Cox 7, Boston, MA 02114, USA. Electronic address: jain@steele.mgh.harvard.edu.

Abstract

Ten antiangiogenic drugs targeting VEGF or its receptors are approved for cancer treatment. However, these agents, intended to block tumors' blood supply, may cause hypoxia, which may fuel tumor progression and treatment resistance. Emerging clinical data suggest that patients whose tumor perfusion or oxygenation increases in response to these agents may actually survive longer. Hence, strategies aimed at alleviating tumor hypoxia while improving perfusion may enhance the outcome of radiotherapy, chemotherapy, and immunotherapy. Here I summarize lessons learned from preclinical and clinical studies over the past decade and propose strategies for improving antiangiogenic therapy outcomes for malignant and nonmalignant diseases.

PMID:
25517747
PMCID:
PMC4269830
DOI:
10.1016/j.ccell.2014.10.006
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center